Understand the source comparison
VIP Help Lung Function Research: Comparison
Bronchodilation pathway VPAC2 receptor → cAMP → PKA inhibition of MLCK Beta-2 adrenergic receptor → cAMP → PKA inhibition of MLCK No direct bronchodilatory effect; reduces inflammation indirectly VIP and beta-2 agonists share the cAMP pathway but act on differ
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Bronchodilation pathway
- VPAC2 receptor → cAMP → PKA inhibition of MLCK
- Beta-2 adrenergic receptor → cAMP → PKA inhibition of MLCK
- No direct bronchodilatory effect; reduces inflammation indirectly
- VIP and beta-2 agonists share the cAMP pathway but act on different receptors. VIP does not cause receptor desensitisation, making it superior for chronic study models
- Anti-inflammatory mechanism
- VPAC1 on T cells → suppressed IL-4/IL-5/IL-13; mast cell stabilisation
- Minimal anti-inflammatory activity; primarily symptomatic
- Inhibits NF-kB and AP-1 → broad cytokine suppression
- VIP's anti-inflammatory profile is narrower than corticosteroids but mechanistically distinct. Ideal for isolating non-steroid-responsive pathways in allergic airway models
- Mucociliary clearance effect
- Increases CBF by 28–35%; enhances CFTR-mediated chloride secretion
- No direct effect on ciliary function
- Reduces mucus hypersecretion indirectly by controlling inflammation
- VIP is the only agent in this comparison that directly stimulates ciliary activity. Critical for CF and bronchiectasis research
- Receptor desensitisation
- Minimal. VPAC receptors maintain 85% activity after 14 days repeated dosing
- Significant. Beta-2 receptors downregulate 40–50% within 7 days
- N/A
- VIP's lack of tachyphylaxis allows long-term mechanistic studies without confounding receptor density changes
- Enzymatic stability
- Extremely unstable. Half-life 1–2 minutes due to DPP-IV and NEP cleavage
- Chemically stable; long circulating half-life
- Stable; lipophilic molecules resist enzymatic degradation
- VIP's instability is a research limitation that requires modified analogs or protease inhibitors in chronic in vivo models
- Primary research application
- Airway smooth muscle physiology, non-adrenergic bronchodilation, mucociliary transport, immune modulation in allergic inflammation
- Acute bronchodilation models, receptor desensitisation studies
- Inflammatory pathway mapping, steroid-resistant asthma models
- VIP fills a mechanistic niche that neither beta-2 agonists nor steroids address. Use it when studying cAMP-independent inflammation or CFTR-related mucus dynamics